Duchenne muscular dystrophy (DMD), an incurable and a progressive muscle wasting
disease, is caused by the absence of dystrophin protein, leading to recurrent muscle fiber …

Skeletal muscle possesses remarkable ability to change its size and force-producing
capacity in response to physiological stimuli. Impairment of the cellular processes that …

Rationale A plethora of compounds potentially leading to drug candidates that affect skeletal
muscle function and, more specifically, mitochondrial biogenesis, has been under (pre) …

Introduction: Since the identification of the dystrophin gene in 1986, a cure for Duchenne
muscular dystrophy (DMD) has yet to be discovered. Presently, there are a number of …

A potentially novel approach for treating obesity includes attenuating myostatin as this
increases muscle mass and decreases fat mass. Notwithstanding, conflicting studies report …

Inhibition of myostatin, which negatively regulates skeletal muscle growth, is a promising
strategy for the treatment of muscle atrophic disorders, such as muscular dystrophy …

Postnatal blockade of the activin type IIB receptor (ActRIIB) represents a promising
therapeutic strategy for counteracting dystrophic muscle wasting. However, its impact on …

Purpose Myostatin is a key regulator of skeletal muscle growth and inhibition of its signaling
pathway results in an increased muscle mass and function. The aim of this study was to …

Aim Muscle atrophy is a common symptom after nerve denervation. Myostatin propeptide, a
precursor of myostatin, has been documented to improve muscle growth. However, the …

The knowledge of the molecular effects of the C313Y mutation, responsible for the “double
muscle” phenotype in Piedmontese cattle, can help understanding the actual mechanism of …